J.P. Morgan
Research head Dan Skovronsky said it’s hard to improve upon tirzepatide, but Lilly is advancing early and late-stage obesity drugs while investigating internal and external assets in weight loss and beyond.
When Zynteglo was approved for beta-thalassemia, bluebird said launch would lay groundwork for sickle cell gene therapy Lyfgenia. The strategy is paying off so far with a fast ramp-up. Outcomes-based contracts for Lyfgenia give payers rebate based on hospitalizations over a three-year period.
The company said when Zynteglo was approved for beta-thalassemia that its launch would lay the groundwork for its sickle cell gene therapy Lyfgenia, and the strategy is paying off so far with a fast ramp-up.
After Alkermes spun out its oncology assets into a separate public entity so the company could focus exclusively on neuroscience, CEO Richard Pops said it will look externally to build its pipeline.
As use of new obesity medicines become more widespread, experts at the J.P. Morgan Healthcare conference predicted that paying for them will stress state governments and employers.
As use of new obesity medicines become more widespread, experts at the J.P. Morgan Healthcare conference predicted that paying for them will stress state governments and employers.
Drug developers weathered a tough 2023, but the year ended with new clarity about interest rates and big pharma M&A priorities, reducing the risk of financial storms in 2024, investors and advisors said.
Drug developers weathered a tough 2023, but the year ended with new clarity about interest rates and big pharma M&A priorities, reducing the risk of financial storms in 2024, investors and advisors said.
Private equity-controlled J B Chemicals and Pharmaceuticals, which recently snapped up a basket of ophthalmology brands from Novartis in India, expects to drive momentum to make key product franchises bigger and stronger, while also building on the CDMO business.
The UK firm's platform has been validated by the partnerships sealed with AstraZeneca and Merck KGaA and the development of an internal five-strong product pipeline, acting CEO Francois Nader told attendees at the J.P. Morgan Healthcare Conference.
Daily notebook from the J.P. Morgan Healthcare Conference: Roche expects continued high interest in partnering; Vir explains cost-cutting gives it a stronger base; bluebird provides Lyfgenia performance to date; Sage details Zurzuvae launch trajectory; and Madrigal lays out next steps in NASH.
The biotech's CEO told the J.P. Morgan Healthcare Conference that the company aims to have multiple oncology products on the market by 2029, but it plans to retain a large presence in vaccines as well.
Daily notebook from the J.P. Morgan Healthcare Conference: Biogen is still looking for deals, just smaller; Sanofi's push in immunology has pulled it away from oncology; Sage provides updates on Zurzuvae launch; and Takeda plans a big program for its TYK-2 inhibitor.
An uptick in deals and an improving macro-economic outlook laid the groundwork for a rosier sentiment across much of the industry at the annual health care conference.
At the J.P. Morgan conference, AbbVie president Robert Michael said the company must effectively integrate ImmunoGen and Cerevel, which it expects to drive long-term growth.
Daily notebook from the J.P. Morgan Healthcare Conference: Novo makes its debut appearance and welcomes newcomers to the obesity market; Novartis weighs its options in obesity; Lilly expects donanemab to launch into a primed Alzheimer's market – and it continues to look for more large-market opportunities; and Apellis sees strong 2023 Syfovre sales.
Daily notebook from the J.P. Morgan Healthcare Conference: Deal and strategy news from Novartis, BMS and Pfizer; Gilead talks lenacapavir PrEP launch plans; BioMarin's new CEO makes an appearance and Saunders explains the status at Bausch + Lomb.